EGFR and posterior cortical atrophy: We previously showed that the pan-ErbB inhibitor dacomitinib was superior to lapatinib in preventing PCa progression (34); however, dacomitinib has greater side effects; hence, we investigated whether lapatinib efficacy could be improved with another low toxic drug.